mRNA Vaxxes and Myocarditis in Young Men By Mrs Vera West
A peer reviewed study that recently appeared in the leading medical journal JAMA Network, has found from a population-based cohort study, based on data from Ontario’s COVID-19 vaccine registry and passive vaccine-safety surveillance system, that there was a statistically significant surge in rates of myocarditis, inflammation of the heart muscles, in young people after the second dose of the mRNA Covid vax. The rates were highest in young men between the ages of 18 and 24 years. This is important for it indicates that a group of people who are at low risk for harms from Covid, if relying upon natural immunity, are facing instead the adverse consequences of the vax. It too, fits into the depopulation agenda.
https://www.naturalnews.com/2022-07-12-mrna-vaccines-increase-risk-myocarditis-young-men.html
“A new peer-reviewed study from Canada has found that rates of myocarditis in young people surge following the second dose of the Wuhan coronavirus (COVID-19) mRNA vaccine.
The study was conducted on adolescents and adults in Ontario. It was a population-based cohort study published in JAMA Network on June 24 and conducted from Dec. 2020 – the beginning of the COVID-19 vaccine rollout – to Sept. 2021. It used data from Ontario’s COVID-19 vaccine registry and passive vaccine-safety surveillance system.
Its goal was to assess the association between specific COVID-19 vaccines to different rates of myocarditis or pericarditis. The researchers also wanted to estimate the rates of myocarditis and pericarditis based on age, sex, dose number and interval period between the vaccine doses.
Myocarditis refers to the inflammation of the heart muscle, a condition that can be life-threatening.
The study found that cases of myocarditis or pericarditis were highest in men between the ages of 18 and 24. Pfizer’s mRNA COVID-19 vaccine caused 59.2 cases per million second doses of the vaccine, while Moderna’s mRNA vaccine caused 299.5 cases per million second doses.
If the vaccine recipients waited eight weeks in between doses, this lowered the second-dose risk of causing myocarditis to 132.5 cases per million second doses for Moderna and 11.1 cases per million for Pfizer.
Study lead author Sarah Buchan of Public Health Ontario in Toronto and her colleagues, who were all still in favor of vaccination, relented slightly by suggesting that longer intervals between doses and that mRNA COVID-19 vaccination programs take into consideration the age and sex of vaccine recipients.
Overall rates of myocarditis or pericarditis across all age groups are 15.6 cases per million first doses and 29 cases per million second doses for Pfizer’s vaccine. The rates are far lower in females – 8.9 and 11.9 cases per million first and second doses – than in males – 21.8 and 45.3 cases per million first and second doses.
For Moderna, myocarditis and pericarditis rates are higher, with 23 cases per million first doses and 62.5 cases per million second doses across all age groups. Females are once again at lessened risk, with only 9.5 and 22 cases per million doses. Men had 33.7 and 96.8 cases per million.
Study confirms COVID-19 vaccines are dangerous for children
This study just lends more credence to the objections of many doctors to letting children, especially male kids and teenagers, from getting the COVID-19 vaccines.
“There is absolutely no basis for giving lethal experimental injections to babies and children,” said Dr. James Thorp, a maternal-fetal medicine expert. “There is absolutely zero epidemiological or clinical data to support this. There is no ’emergency use authorization’ when there is no emergency.”
“The COVID-19 injections were never necessary,” continued Thorp. He believes the COVID-19 vaccines have caused significantly much more harm than good and that people should be looking into non-vaccine treatments for the coronavirus that are actually effective.
“The scientific verdict is in,” said Thorp. “Ninety-five percent of COVID-19 deaths are prevented by early therapies with nutraceuticals, vitamins and repurposed medications.”
“Another peer-reviewed study based on passive surveillance from Ontario, Canada, found that the rate of myocarditis was greater in younger males than females, and also greater after the second dose than the first dose of an mRNA vaccine.
On June 17, the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for Moderna and Pfizer vaccines for children as young as 6 months old.
On June 24, the CDC (Centers for Disease Control and Prevention) started recommending COVID vaccines to everyone aged 6 months or older and COVID-19 boosters for “everyone ages 5 years and older.”
Dr. Sanjay Verma, a cardiologist from California, told The Epoch Times that the agency is doing this “regardless of risk stratification or prior infection with SARS-CoV2. Using data mostly from VAERS, supplemented with VSD (Vaccine Safety Datalink) data, CDC continues to assert that the COVID-19 vaccines are ‘safe and effective.'”
Previous studies have shown rapidly decreasing vaccine efficacy (VE) in children as well as adolescents during the first few months after completing vaccination.
“The decreasing VE then begs the question if the benefits outweigh the risks in healthy children and young adults given the known increased, albeit rare, risk of myocarditis,” Verma said.
The study had the goal of assessing the association between specific vaccine products to differences in rates of myocarditis or pericarditis; Further estimating the rates based on age, sex, dose number, and interval between the shots.
The study found 97.3 cases of myocarditis per million doses of BNT162b2 (Pfizer) for 12–17-year-old males and 299.5 per million doses of mRNA-1273 (Moderna) for 18–24-year-old males.
The population-based cohort study was published on June 24 and conducted from December 2020 to September 2021 and used data from Ontario’s COVID-19 vaccine registry and passive vaccine-safety surveillance system.
“As the authors also mention in the discussion, this is substantially higher than the VAERS data reported by CDC (38.5 per million for mRNA-1273 doses in males and 69.1 per million BNT162b2 doses for males 16-17 years old,)” Verma said.
“Furthermore, the authors continue, using data from four claims databases, FDA reported a rate of 283 cases of myocarditis per million of mRNA-1271 doses for males 18-25 years old. This is closer to the rate found in this study (299.5 per million). Vaccine Safety Data (VSD) data, the authors note, found the adjusted rate of myocarditis or pericarditis to be 2.72 times greater for dose 2 of mRNA-1273 than dose 2 of BNT162b2.”
Child Vaccination
Dr. James Thorp, a maternal-fetal medicine expert, believes that children should not take the vaccine.
Thorp told The Epoch Times that: “There is absolutely no basis for giving lethal experimental injections to babies and children. There is absolutely zero epidemiological or clinical data to support this. There is no ’emergency use authorization’ when there is no emergency.”
Thorp thinks that the vaccines would cause much more harm than good, and that the Chinese Communist Party virus can be treated with other methods.
“The COVID-19 injections were never necessary. The scientific verdict is in and 95 percent of COVID-19 deaths are prevented by early therapies with nutraceuticals, vitamins, and repurposed medications,” Thorp said.
The CDC’s Interim Clinical Considerations said in regards to issues of interchangeability of shots from different manufacturers (when one takes a first dose from Pfizer and then a second form Moderna), that “in exceptional situations in which the mRNA vaccine product administered for a previous dose(s) of the primary series cannot be determined or is not available, any age-appropriate mRNA COVID-19 vaccine product may be administered.”
And as for the vaccine boosters, the CDC’s recommendations are, “Any age-appropriate mRNA vaccine can be used for the booster dose(s): it can be the same mRNA vaccine as the primary series (homologous booster dose) or a different mRNA vaccine (heterologous booster dose).”
“However,” Verma said: “In the Supplementary Online Content of this study, the authors report that when vaccines are mixed (i.e., dose 1 and dose 2 are different manufacturers), the rate of myocarditis can be as high as 799 per million if mRNA-1273 is the second dose after initial BNT162b2 dose. The risk with heterologous dosing thus is 2.67 times higher than homologous dosing.”
Myocarditis refers to the inflammation of the heart muscle—a life-threatening condition. There are many established causes for this heart condition. The leading cause—according to modern science’s most recent discoveries—is viruses; but during the pandemic, COVID mRNA vaccines have earned a place as a top suspect for myocarditis.
New York Protests
On Wednesday, about 20 police barricaded a vaccine center in New York due to demonstrators protesting against the COVID vaccination of babies and children.
On July 2, protestors were recorded outside a vaccination center in Times Square begging parents taking their children into the center not to vaccinate them and asking them to do more research before doing a potentially irreversible medical procedure.”
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2793551
“Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada
Sarah A. Buchan, PhD1,2,3; Chi Yon Seo, MSc1; Caitlin Johnson, MPH1; et alSarah Alley, MPH1; Jeffrey C. Kwong, MD1,2,3,4,5; Sharifa Nasreen, PhD2,3; Andrew Calzavara, MSc3; Diane Lu, MD1; Tara M. Harris, MHSc1; Kelly Yu, MPH1; Sarah E. Wilson, MD1,2,3
Author Affiliations Article Information
JAMA Netw Open. 2022;5(6):e2218505. doi:10.1001/jamanetworkopen.2022.18505
Key Points
Question Do rates of reported myocarditis or pericarditis following COVID-19 mRNA vaccination vary by vaccine product and interdose interval?
Findings This population-based cohort study of 297 individuals in Ontario, Canada, with myocarditis or pericarditis following COVID-19 vaccination found higher rates of myocarditis or pericarditis associated with receipt of mRNA-1273 compared with BNT162b2 as a second dose, particularly among male individuals aged 18 to 24 years. Higher rates were also observed with shorter interdose intervals.
Meaning The results suggest that there may be product-specific differences in rates of myocarditis or pericarditis after receiving mRNA vaccines and that programmatic strategies may be associated with reduced risk of myocarditis or pericarditis after receiving mRNA vaccines.
Abstract
Importance Increased rates of myocarditis or pericarditis following receipt of COVID-19 mRNA vaccines have been observed. However, few available data are associated with differences in rates of myocarditis or pericarditis specific to vaccine products, which may have important implications for vaccination programs.
Objective To estimate rates of reported myocarditis or pericarditis following receipt of a COVID-19 mRNA vaccine by product, age, sex, dose number, and interdose interval.
Design, Setting, and Participants This population-based cohort study was conducted in Ontario, Canada (population: 14.7 million) from December 2020 to September 2021 and used data from Ontario’s COVID-19 vaccine registry and passive vaccine-safety surveillance system. All individuals in Ontario, Canada, who received at least 1 dose of COVID-19 mRNA vaccine between December 14, 2020, and September 4, 2021, and had a reported episode of myocarditis or pericarditis following receipt of the COVID-19 vaccine during this period were included. We obtained information on all vaccine doses administered in the province to calculate reported rates of myocarditis or pericarditis.
Exposures Receipt of a COVID-19 mRNA vaccine (mRNA-1273 [Moderna Spikevax] or BNT162b2 [Pfizer-BioNTech Comirnaty]).
Main Outcomes and Measures All reports of myocarditis or pericarditis meeting levels 1 to 3 of the Brighton Collaboration case definitions were included. Rates and 95% CIs of reported cases of myocarditis or pericarditis per 1 000 000 mRNA vaccine doses administered were calculated by age, sex, dose number, vaccine product, and interdose interval.
Results Among 19 740 741 doses of mRNA vaccines administered, there were 297 reports of myocarditis or pericarditis meeting the inclusion criteria; 228 (76.8%) occurred in male individuals, and the median age of individuals with a reported event was 24 years (range, 12-81 years). Of the reported cases, 207 (69.7%) occurred following the second dose of the COVID-19 mRNA vaccine. When restricted to individuals who received their second dose during the period of enhanced passive surveillance (on or after June 1, 2021), the highest rate of myocarditis or pericarditis was observed in male individuals aged 18 to 24 years following mRNA-1273 as the second dose (299.5 cases per 1 000 000 doses; 95% CI, 171.2-486.4 cases per 1 000 000 doses); the rate following BNT162b2 as the second dose was 59.2 cases per 1 000 000 doses (95% CI, 19.2-138.1 cases per 1 000 000 doses). Overall rates for both vaccine products were significantly higher when the interdose interval was 30 or fewer days (BNT162b2: 52.1 cases per 1 000 000 doses [95% CI, 31.8-80.5 cases per 1 000 000 doses]; mRNA-1273: 83.9 cases per 1 000 000 doses [95% CI, 47.0-138.4 cases per 1 000 000 doses]) compared with 56 or more days (BNT162b2: 9.6 cases per 1 000 000 doses [95% CI, 6.5-13.6 cases per 1 000 000 doses]; mRNA-1273: 16.2 cases per 1 000 000 doses [95% CI, 10.2-24.6 cases per 1 000 000 doses]).
Conclusions and Relevance The findings of this population-based cohort study of Ontario adolescents and adults with myocarditis or pericarditis following mRNA COVID-19 vaccination suggest that vaccine products and interdose intervals, in addition to age and sex, may be associated with the risk of myocarditis or pericarditis after receipt of these vaccines. Vaccination program strategies, such as age-based product considerations and longer interdose intervals, may reduce the risk of myocarditis or pericarditis following receipt of mRNA vaccines.”
Comments